Management of Dental Patients Taking Anticoagulants or Antiplatelet Drugs
Published August 2015
Guidance under review – see below for details
- Full Guidance (PDF) – provides comprehensive background information, recommendations and practical advice. An accessible version (Word) is also available.
- Quick Reference Guide (PDF) – summarises the main recommendations from the full guidance in a treatment planning flow-chart. An accessible version (Word) is also available.
Also available via the SDCEP Dental Companion app.
A number of supporting tools are included with the full guidance to assist the dental team to implement the guidance recommendations. These are available for download and printing:
- Patient Information Leaflets – explain to the patient the importance of advising their dental practitioner of their medication and how their dental treatment may be affected by the drugs:
- Warfarin and Your Dental Treatment (PDF). Also available for printing as a double-sided A5 leaflet (PDF) and as an accessible version (Word).
- Antiplatelet Drugs and Your Dental Treatment (PDF). Also available for printing as a double-sided A5 leaflet (PDF) and as an accessible version (Word).
- NOACs and Your Dental Treatment (PDF). Also available for printing as a double-sided A5 leaflet (PDF) and as an accessible version (Word).
- Post-Treatment Advice Sheets for Patients – advice sheets to which local emergency contact details can be added:
- Post-Treatment Advice for Patients Taking Warfarin (PDF). Also available as an accessible version (Word).
- Post-Treatment Advice for Patients Taking Antiplatelet Drug(s) (PDF). Also available as an accessible version (Word).
- Post-Treatment Advice for Patients Taking a Novel Oral Anticoagulant (NOAC) (PDF). Also available as an accessible version (Word).
- Local Contacts for Advice and Referral (Word) – a template form for recording local contact details for medical, pharmacy, haematology, cardiology and secondary dental care support. Also available as an accessible version (Word).
Printed copies of the Full Guidance and Quick Reference Guide are available.
About this guidance
Management of Dental Patients Taking Anticoagulants or Antiplatelet Drugs provides recommendations and practical advice to inform bleeding risk assessment and decision making for the treatment of this patient group. Information about the newer generation anticoagulants and antiplatelet drugs as well as the more established medications is included.
The guidance is aimed primarily at dentists, hygienists and therapists in primary care dental practice and will also be of relevance to the secondary care dental service, those involved in dental education and undergraduate trainees.
The guidance is based on a review of available evidence and the opinion of dental and medical experts and experienced practitioners and has been subject to open consultation prior to finalising for publication. The methodology used for the development of this guidance, including details of the evidence search strategy, evidence appraisals and information about conflict of interests can be found in the Anticoagulants Guidance Development Methodology (PDF) document. Further information on the SDCEP guidance development process is available or contact the SDCEP office (firstname.lastname@example.org).
During the development process, potential barriers to the implementation of this guidance were identified. A Guidance Implementation Summary (PDF) of information about these is provided. For further details visit the TRiaDS website.
NICE has accredited the process used by the Scottish Dental Clinical Effectiveness Programme to produce its Management of Dental Patients Taking Anticoagulants or Antiplatelet Drugs guidance. Accreditation is valid for 5 years from 15 March 2016. More information on accreditation can be viewed at www.nice.org.uk/accreditation. Further information about NICE accreditation of SDCEP guidance can be viewed at NICE Accreditation.
Guidance Development Group
A multidisciplinary Guidance Development Group, consisting of individuals from a range of branches of the dental and medical professions together with a patient representative, was convened to develop and write this guidance, assisted by our Programme Development Team.
|Garry Sime (Chair)||Senior Dental Officer and Specialist in Special Care Dentistry, NHS Tayside|
|Carol Armstrong||Dental Tutor Therapist, UHISOHS, NHS Dumfries & Galloway|
|Dean Barker||Consultant in Restorative Dentistry/Honorary Clinical Senior Lecturer, University of Aberdeen Dental School and Hospital|
|Adrian Brady||Consultant Cardiologist, NHS Greater Glasgow & Clyde; Associate Professor, University of Glasgow|
|Patricia Green||Patient Representative and Anticoagulation Europe (ACE) Local Patient Contact, Aviemore|
|Steven Johnston||Salaried Dental Officer, Public Dental Service, NHS Orkney|
|Douglas Kennedy||Consultant in Oral & Maxillofacial Surgery, NHS Tayside|
|Clare Marney||Consultant in Oral Medicine, Dundee Dental Hospital and School|
|Steve McGlynn||Specialist Principal Pharmacist (Cardiology), NHS Greater Glasgow & Clyde; Honorary Senior Teaching Fellow, University of Strathclyde|
|Namita Nayyer||Specialty Registrar in Oral Surgery, Dundee Dental Hospital and School|
|Avril Neilson||Consultant in Oral Surgery, Dundee Dental Hospital and School|
|Gillian Nevin||General Dental Practitioner, Coupar Angus; Assistant Director of Postgraduate GDP Education, Dundee Dental Education Centre|
|Christine Randall||Senior Medicines Information Pharmacist and UKMi Representative, North West Medicines Information Centre, Liverpool|
|Simon Randfield||General Practitioner, NHS Forth Valley|
|Petrina Sweeney||Senior Lecturer/Honorary Consultant in Special Care Dentistry, University of Glasgow Dental School|
|Campbell Tait||Consultant Haematologist, NHS Greater Glasgow & Clyde|
|Liz Theaker||Consultant in Oral Medicine, Dundee Dental Hospital and School|
|John Wall||General Dental Practitioner, Perth|
Review and updating
The SDCEP Management of Dental Patients Taking Anticoagulants or Antiplatelet Drugs guidance was first published in 2015. In line with SDCEP’s standard five year guidance review period, the scheduled review of the guidance topic commenced in 2020. The evidence searches are being updated and information on practitioners’ experience of treating relevant patient groups is being sought. The Guidance Development Group will reconvene in 2021 to consider developments relating to the topic, review new evidence and information and update the guidance.